Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

183.17B

Market cap183.17B

Price-Earnings ratio

-55.59

Price-Earnings ratio-55.59

Dividend yield

2.20%

Dividend yield2.20%

Average volume

5.11M

Average volume5.11M

High today

$149.30

High today$149.30

Low today

$146.12

Low today$146.12

Open price

$146.58

Open price$146.58

Volume

5.19M

Volume5.19M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$108.46

52 Week low$108.46

Stock Snapshot

With a market cap of 183.17B, Gilead Sciences(GILD) trades at $147.15. The stock has a price-to-earnings ratio of -55.59 and currently yields dividends of 2.20%.

As of 2026-09-17, Gilead Sciences(GILD) stock has fluctuated between $146.12 and $149.30. The current price stands at $147.15, placing the stock +0.7% above today's low and -1.4% off the high.

Gilead Sciences(GILD) shares are trading with a volume of 5.19M, against a daily average of 5.11M.

During the past year, Gilead Sciences(GILD) stock moved between $108.46 at its lowest and $157.29 at its peak.

GILD News

Zacks 17h

Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America - Zacks Investment Research

...

TipRanks 18h

Gilead announces expanded scope of licensing agreements for lenacapavir

Gilead (GILD) Sciences announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigationa...

Simply Wall St 23h

Should Gilead Sciences Reconsider Its Global HIV Case After This PAHO Deal?

Gilead Sciences (NasdaqGS:GILD) announced a partnership with the Pan American Health Organization to expand access to lenacapavir for HIV prevention. The agree...

Analyst ratings

77%

of 30 ratings

Buy

76.7%

Hold

20%

Sell

3.3%

More GILD News

TipRanks 2d

Gilead announces agreement with PAHO for lenacapavir access

Gilead (GILD) Sciences announced a new agreement with the Pan American Health Organization, or PAHO, to accelerate access to twice-yearly lenacapavir for HIV pr...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

WisdomTree Japan Hedged E…

Cadence Design Systems

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.